Literature DB >> 8396091

Single-dose oral azithromycin versus seven-day doxycycline in the treatment of non-gonococcal urethritis in males.

J Lauharanta1, K Saarinen, M T Mustonen, H P Happonen.   

Abstract

One hundred and twenty male patients with signs and symptoms compatible with non-gonococcal urethritis were enrolled in a prospective-randomized study to compare the efficacy and safety of a single oral-dose of 1 g azithromycin and a seven-day course of 100 mg doxycycline twice-daily. Clinical examination and culture samples for Chlamydia trachomatis were performed before and approximately 8, 15 and 35 days after starting treatment. Both treatment groups were comprised of 30 chlamydia-positive patients evaluable for efficacy. The eradication rate of C. trachomatis in baseline-positive patients at the first follow-up visit in the azithromycin group was 96% with one persistent case, and 100% in the doxycycline group. After about two weeks, there were two re-occurrences in the azithromycin group, resulting in a cumulative eradication rate of 90% with three culture-positive cases. The corresponding figure in the doxycycline group was still 100%, but there were leucocytes present in the urethral smear of two patients who later proved to be true culture-positive re-occurrences. After about five weeks, there was an additional re-occurrence in the azithromycin group leading to a cumulative eradication rate of 87%, while two re-occurrences in the doxycycline group gave a cumulative eradication rate of 93%. There was no statistically significant difference in efficacy between the single-dose azithromycin and seven-day course of doxycycline in the treatment of patients with chlamydial urethritis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396091     DOI: 10.1093/jac/31.suppl_e.177

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Control of genital chlamydial infection.

Authors:  P R Gully; R W Peeling
Journal:  Can J Infect Dis       Date:  1994-05

Review 2.  Sexually transmitted infections.

Authors:  C Carne
Journal:  BMJ       Date:  1998-07-11

Review 3.  Chlamydiae as pathogens: new species and new issues.

Authors:  R W Peeling; R C Brunham
Journal:  Emerg Infect Dis       Date:  1996 Oct-Dec       Impact factor: 6.883

Review 4.  Concurrent gonococcal and chlamydial infection: how best to treat.

Authors:  A J Robinson; G L Ridgway
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 5.  Practical recommendations for the drug treatment of bacterial infections of the male genital tract including urethritis, epididymitis and prostatitis.

Authors:  M L Joly-Guillou; S Lasry
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 6.  Drug therapies for sexually transmitted diseases. Clinical and economic considerations.

Authors:  W R Bowie
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

7.  Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.

Authors:  U Dreses-Werringloer; I Padubrin; H Zeidler; L Köhler
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  Azithromycin levels in cervical mucus and plasma after a single 1.0g oral dose for chlamydial cervicitis.

Authors:  A M Worm; A Osterlind
Journal:  Genitourin Med       Date:  1995-08

9.  Periodic health examination, 1996 update: 2. Screening for chlamydial infections. Canadian Task Force on the Periodic Health Examination.

Authors:  H D Davies; E E Wang
Journal:  CMAJ       Date:  1996-06-01       Impact factor: 8.262

10.  Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study.

Authors:  T K Kvien; J S H Gaston; T Bardin; I Butrimiene; B A C Dijkmans; M Leirisalo-Repo; P Solakov; M Altwegg; P Mowinckel; P-A Plan; T Vischer
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.